Swedish Innovation Pexa Device Promises Early Detection of Lung Diseases

In Sweden, where an estimated 1.3 million people live with lung diseases often undiagnosed, a groundbreaking technology offers hope for earlier detection and better outcomes. The device, called Pexa, collects particles from the smallest airways in the lungs — the very sites where many lung diseases begin. Developed and deployed in research settings since 2017, notably at Lund University, this approach is currently used to differentiate between healthy and diseased lungs, including lung cancer cases.

Åsa Edman from Gothenburg is a poignant example of the challenges posed by late diagnosis; she lived with Chronic Obstructive Pulmonary Disease (COPD) for years without knowing it. Edman expressed regret over missed opportunities to manage her health earlier, stating, "If I had known in time how I could have lived, I would have made many different choices." Experts highlight that current methods only gauge lung capacity without revealing underlying causes, making early diagnosis difficult.

Thoracic surgeon Sandra Lindstedt at Lund University is optimistic about Pexa’s future, hoping to evolve it into a screening tool similar to mammography for breast cancer — a preventive measure to identify at-risk individuals before symptoms arise. CEO of Pexa, Tomas Gustafsson, emphasizes the device’s potential to provide earlier, more precise diagnoses which could transform lung disease management. Edman hopes that early identification will empower people to take responsibility for their health, potentially reducing the burden of chronic lung conditions across Sweden.

This innovation marks a significant advancement in respiratory health, offering a new pathway for early intervention and improved patient outcomes, with ongoing research aimed at integrating Pexa into routine screening protocols.